EGFR and metastatic neoplasm: Moreover, while for metastatic disease, CMS4 tumors are resistant to anti-EGFR therapies (irrespective of KRAS mutational status) and to doublet/triplet backbone chemotherapy, the benefit of adjuvant treatment for early and locally advanced CMS4 tumors is not obvious [39,40,41,42].